Versant Venture Capital VI, L.P.'s Form 4 filing
LENZ Therapeutics, Inc. (LENZ) · filed Sep 22, 2025
- Accession no.
- 0001193125-25-211363
- Filed
- Sep 22, 2025, 4:23 PM ET
- Trade date
- Sep 18, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 6 non-derivative transactions. Open-market sales total $5.71M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Versant Venture Capital VI, L.P.CIK 0001687880 | 10% Owner |
| Versant Venture Capital VII, L.P.CIK 0001750266 | 10% Owner |
| Versant Ventures VI GP-GP, LLCCIK 0001777652 | 10% Owner |
| Versant Ventures VI GP, L.P.CIK 0001777654 | 10% Owner |
| Versant Ventures VII GP, L.P.CIK 0001777655 | 10% Owner |
| Versant Ventures VII GP-GP, LLCCIK 0001777656 | 10% Owner |
| Versant Vantage II, L.P.CIK 0001832235 | 10% Owner |
| Versant Vantage II GP-GP, LLCCIK 0001839789 | 10% Owner |
| Versant Vantage II GP, L.P.CIK 0001839790 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 18, 2025 | Common Stock | SSaleDisposed | −49,479 | $41.59F1 | −$2,057,871.19 | 1,224,718 | Direct | |
| Sep 18, 2025 | Common Stock | SSaleDisposed | −24,370 | $41.59F1 | −$1,013,567.8 | 876,437 | Indirect | |
| Sep 18, 2025 | Common Stock | SSaleDisposed | −40,907 | $43.00F4 | −$1,759,156.45 | 1,183,811 | Direct | |
| Sep 18, 2025 | Common Stock | SSaleDisposed | −20,148 | $43.00F4 | −$866,440.56 | 856,289 | Indirect | |
| Sep 18, 2025 | Common Stock | SSaleDisposed | −268 | $43.30 | −$11,604.4 | 1,183,543 | Direct | |
| Sep 18, 2025 | Common Stock | SSaleDisposed | −132 | $43.30 | −$5,715.6 | 856,157 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $41.25 to $42.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
Referenced by the price of 2 transactions in Table I.
- F4
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $42.25 to $43.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
Referenced by the price of 2 transactions in Table I.